SAN FRANCISCO, CALIFORNIA, 9 January 2023 – Complete Genomics Inc, a subsidiary of MGI Tech Co., Ltd. (MGI), today unveiled its full sequencing platform portfolio at Biotech Showcase during JP Morgan Healthcare Conference Week 2023.
Rade Drmanac, PhD, Chief Scientific Officer of Complete Genomics, announced a free three-month trial programme and a reagent rental leasing programme, giving customers the opportunity to evaluate the quality and reliability of its products before purchase.
About Complete Genomics
Founded in 2005 in Silicon Valley, Complete Genomics is a leading innovator in high-throughput sequencing technologies, offering end-to-end multi-omics platforms spanning genetic sequencing and laboratory automation. The company developed its proprietary DNA nanoball-based sequencing technology, DNBSEQ™.
DNBSEQ technology uses DNA nanoballs (DNBs) with high signal density arranged on patterned nanoarrays to significantly improve detection accuracy and efficiency. It delivers strong performance in applications such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), with low duplication rates and higher indel accuracy. The technology eliminates index hopping and clonal amplification errors during sequencing, enabling greater accuracy and workflow flexibility.
DNBSEQ Platforms Available in the US
- DNBSEQ-G400C*: Medium-throughput benchtop sequencer for day-to-day use with flexible sequencing modes, launched in the US last year.
- DNBSEQ-E25*: Portable, low-throughput sequencer delivering up to 7.5 Gb per day. Ten-minute setup with ~20-hour turnaround from DNA sample to FASTQ data. Launching Q2 2023.
- DNBSEQ-T7*: Ultra-high throughput sequencer with four independent flow cells, producing 1–7 Tb of data per day, capable of 20,000 30× WGS datasets in under a year. Available now.
- DNBSEQ-T10x4*: One of the world’s largest and highest-throughput sequencers with robotic arm and up to 18 Tb daily output. Available now.
Complete Genomics provides a comprehensive NGS solution, covering the full workflow from lab automation to data analysis and storage to accelerate scientific discovery and genomic medicine.
Partnerships and Adoption
DNBSEQ technology’s accuracy, flexibility and affordability has attracted strong interest from the scientific community, including partnerships with life science companies such as Sentieon.
“Complete Genomics delivers high-quality, accurate and accessible sequencing platforms, giving the genomics community the power of choice,” said Jun Ye, CEO of Sentieon. “We look forward to supporting future innovation through continued collaboration.”
“We do not simply sell instruments. We enable partners by understanding market needs, offering early access to new platforms and building strong local collaborations. Our goal is to advance life science globally by giving researchers a real alternative,” said Dr Drmanac.
Trial and Leasing Programmes
The free three-month trial programme allows participating institutions to access selected sequencing platforms with a money-back guarantee. Qualified professionals may apply for the reagent rental leasing programme to reduce upfront investment. For further information, contact sales@completegenomics.com.
Data Security
All DNBSEQ platforms can operate fully stand-alone from sample to result without an internet connection, ensuring complete customer control and eliminating data breach risk.
Company Overview
Complete Genomics Inc, a subsidiary of MGI Tech Co., Ltd., is a global life science company providing laboratory automation and a comprehensive high-throughput sequencing portfolio. Founded in June 2005 and headquartered in San Jose, California, the company operates a demo laboratory and supply centre in the US. The DNBSEQ-G400C* was the first next-generation sequencing platform released in the US, in August 2022. For full specifications, visit the Complete Genomics website.
* Unless otherwise stated, StandardMPS and CoolMPS sequencing reagents and compatible sequencers are not available in Germany, Spain, the UK, Sweden, Belgium, Italy, Finland, the Czech Republic, Switzerland, Portugal, Austria and Romania. StandardMPS reagents and compatible sequencers are not available in Hong Kong. Products are for research use only. Not for diagnostic use.
